VAXIMM is developing oral T-cell immunotherapies for cancer patients. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria carrying a eukaryotic expression plasmid which enables targeting of tumor-related antigens including personalized neoantigens

Location

Hochbergerstrasse 60C, 4057 Basel

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2008

  • Number of employees in Switzerland

    1-9

Key business

You may also be interested in